www.hivandhepatitis.com

Back HCV Treatment

New England Journal of Medicine Publishes Promising Data from PROVE 1 and PROVE 2 Studies of HCV Protease Inhibitor Telaprevir

Details
Category: HCV Treatment
Published on Tuesday, 12 May 2009 14:01
Written by Liz Highleyman
  • Print

Several directly targeted oral antiviral agents are currently under study for the treatment of chronic hepatitis C virus (HCV) infection, with the HCV NS3/4A serine protease inhibitor telaprevir (formerly known as VX-950) expected to be the first out of the pipeline. Telaprevir is being developed by Vertex Pharmaceuticals in collaboration with Tibotec and Mitsubishi Tanabe Pharma.

alt

Read more:

Subcategories

Copyright © 2025 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design